Theravance Biopharma
TBPH
86 hedge funds and large institutions have $1.08B invested in Theravance Biopharma in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 12 closing their positions.
311% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $537K
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
0.14% more ownership
Funds ownership: 87.05% → 87.19% (+0.14%)
4% less funds holding
Funds holding: 90 → 86 (-4)
6% less capital invested
Capital invested by funds: $1.16B → $1.08B (-$72.2M)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$28M |
| 2 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$7.48M |
| 3 |
BlackRock
New York
|
+$3.98M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.03M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.4M |
| 2 |
FAM
Foundation Asset Management
White Plains,
New York
|
-$8.84M |
| 3 |
Goldman Sachs
New York
|
-$5.88M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$5.22M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$3.81M |
TBPH Hedge Fund Activity: Q2 2018 in Review
86 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2018, worth a combined $1.08B — down 6.2% from $1.16B a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TBPH and 8 opened new positions — a net loss of 4 holders — while 27 trimmed existing stakes and 32 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $28M. The largest seller was T. Rowe Price Associates, cutting an estimated $14.4M.
- 86 institutional investors held Theravance Biopharma (TBPH) as of Q2 2018, down from 90 in Q1 2018.
- Funds reported $1.08B of Theravance Biopharma stock for Q2 2018, down 6.2% quarter-over-quarter.
- 8 funds opened new Theravance Biopharma positions in Q2 2018 and 12 closed out, a net change of -4 holders.
- The largest Theravance Biopharma buyer in Q2 2018 was Armistice Capital, an estimated $28M added.
- The largest Theravance Biopharma seller in Q2 2018 was T. Rowe Price Associates, an estimated $14.4M sold.
Based on aggregated 13F filings for Q2 2018.